Kehoe Law Firm, P.C. is investigating whether certain executive officers and directors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) breached their fiduciary duties by failing to manage Revance in an acceptable manner and whether Revance and its shareholders were harmed as a result.

Key Issues Under Investigation

The investigation concerns whether Revance’s officers and directors made materially false and misleading statements or failed to disclose critical information regarding:

1. Breach of the Distribution Agreement – Whether Revance materially breached its distribution agreement with Teoxane SA, thereby increasing the company’s risk of litigation; and
2. Potential Delay or Amendment of the Tender Offer – Whether the Tender Offer, pursuant to a merger agreement with Crown Laboratories, Inc., was likely to be delayed or amended due to a breach of the distribution agreement.

Revance Stock Investors: Learn More About the Investigation and Your Legal Options 

To learn more about the investigation or discuss potential legal claims, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Our class action legal services are on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

A federal securities class action has been filed against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents issued in connection with the company’s initial public offering (“IPO”) and suffered damages as a result.

The lawsuit asserts strict liability claims under the Securities Act of 1933 related to Neumora’s IPO, which commenced on or about September 15, 2023, offering 14,710,000 shares of common stock at a price of $17.00 per share.

Allegations Against Neumora 

Acccording to the complaint, the Offering Documents failed to disclose and/or misrepresented the following significant, then-existing material events, trends, and uncertainties regarding the prospects of Navacaprant as a monotherapy, including:

1. Changes to Trial Inclusion Criteria – To justify conducting its Phase Three Program, Neumora had to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder (“MDD”) to show that Navacaprant offered a statistically significant improvement in treating MDD.

2. Modification to Statistical Analysis – Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD.

3. Insufficient Phase Two Trial Data – The Phase Two Trials lacked adequate data, particularly regarding patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Investors Who Acquired NMRA Stock May Have Legal Claims

Investors who acquired Neumora common stock pursuant or traceable to the company’s IPO may have legal claims. To learn more about the Neumora class action or explore your legal options, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Kehoe Law Firm’s legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating whether certain executive officers and directors of Warner Bros. Discovery, Inc. (“Warner Bros.” or “WBD”) (NASDAQ: WBD) failed to manage Warner Bros. in an acceptable manner, in breach of their fiduciary duties to Warner Bros. and whether WBD and its shareholders were harmed as a result.

Warner Bros., Media Rights, and the NBA 

The breach of fiduciary duties investigation concerns whether WBD made materially false and misleading statements regarding its business prospects, particularly its media rights negotiations with the National Basketball Association (“NBA”) and the financial health of its Networks Segment.

More specifically, the investigation concerns whether WBD and its executives misled investors by failing to disclose key risks, including:

1. The likelihood that the NBA negotiations would require a major reassessment of WBD’s business operations and goodwill valuations;
2. The deterioration of the Networks Segment’s goodwill due to the gap between WBD’s market capitalization and book value; weakness across U.S. advertising markets; and uncertainty surrounding affiliate relationships and sports rights renewals, especially regarding the NBA contract;
3. The increased probability of goodwill impairment charges amounting to billions of dollars;
4. Whether these factors, if not disclosed, resulted in an artificially inflated and misleading portrayal of WBD’s financial position.

Current Warner Bros. Stock Investors: Learn More About the Investigation and Your Legal Options 

To learn more about the investigation or discuss potential legal claims, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Our class action legal services are on a contingency-fee basis, meaning you are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating whether certain executive officers and directors of Hasbro, Inc. (“Hasbro” or the “Company”) (NASDAQ: HAS) failed to manage Hasbro in an acceptable manner, in breach of their fiduciary duties to Hasbro and whether the Company and its shareholders were harmed as a result.

On February 5, 2025, a shareholder derivative complaint was filed against certain officers and directors of Hasbro, Inc. seeking to remedy their alleged violations of federal law and breaches of fiduciary duty which occurred between at least February 7, 2022 and October 25, 2023 (the “Relevant Period”).

Allegedly, Hasbro, a multinational toy and entertainment company, experienced a surge in demand for its products during the COVID-19 pandemic due to lockdowns and stay-at-home orders, leading to excess inventory.

The company accumulated this inventory to meet anticipated demand, but contrary to repeated statements by company management, its inventories were not of “good quality” and far exceeded customer demand.

On January 26, 2023, the Company reported disappointing Q4 2022 results and announced a 15% global workforce reduction, causing its stock to drop by 8.1%. Despite this, the Company’s stock remained artificially inflated because the individual defendants, allegedly, continued to obscure the truth.

The full truth emerged on October 26, 2023, when Hasbro revealed poor Q3 2023 results, lowered full-year revenue guidance, and disclosed costs associated with managing inventory. This led to an 11.7% drop in stock price.

Long-Term Hasbro Shareholders: Know Your Rights and Legal Options 

To learn more about the shareholder derivative action or discuss potential legal claims, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Our class action legal services are on a contingency-fee basis, meaning you are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Novo Nordisk investors should be aware that on January 24, 2025, a class action lawsuit was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk”) (NYSE: NVO) securities between November 2, 2022, and December 19, 2024, inclusive (the “Class Period”). This lawsuit seeks to recover damages caused by Defendants’ alleged violations of federal securities laws.

What Can You Do if You Purchased or Acquired Novo Nordisk Securities During the Class Period?

If you purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024 and suffered losses, you may be eligible to participate in this class action lawsuit.

Get More Information or Speak with an Attorney

To learn more about the class action lawsuit or to find out if you’re eligible to participate, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], for a free, no-obligation evaluation of your potential claims.

Alternatively, you can email [email protected] or complete our online confidential Securities Class Action Questionnaire, and you will be contacted by a legal professional.

Class Action Allegations

The Novo Nordisk class action alleges that Defendants misled investors about the Phase 3 CagriSema obesity study, “REDEFINE-1.” The lawsuit claims that critical details about the flexible dosing protocol in the study were not disclosed to investors, including the fact that patients could adjust their doses during the trial. As a result, Novo Nordisk’s stock traded at artificially inflated prices during the Class Period.

On December 20, 2024, Novo revealed disappointing results from the REDEFINE-1 trial, revealing a 22.7% average weight loss instead of the anticipated 25% average weight loss for obesity patients treated with CagriSema in the study.

Following this announcement, Novo Nordisk’s stock price fell sharply by 17.83%, from $103.44 per share on December 19, 2024 to $85.00 per share on December 20, 2024.

To view the complaint, click Novo Nordisk class action complaint.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

All legal consultations are completely free and with no obligation to pursue a case. Legal services are provided on a contingency-fee basis, meaning you are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]